These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1530 related articles for article (PubMed ID: 15210403)

  • 1. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
    Kamphuisen PW; Agnelli G
    Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of venous thromboembolic disease. The impact of low-molecular-weight heparin.
    Tapson VF; Hull RD
    Clin Chest Med; 1995 Jun; 16(2):281-94. PubMed ID: 7656540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
    Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism.
    Grau E; Tenias JM; Real E; Medrano J; Ferrer R; Pastor E; Selfa S
    Am J Hematol; 2001 May; 67(1):10-4. PubMed ID: 11279651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
    Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB
    CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
    Nishioka J; Goodin S
    J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Thrombophilia, preeclampsia and other pregnancy complications].
    Vucić N; Frleta M; Petrović D; Ostojić V
    Acta Med Croatica; 2009 Oct; 63(4):297-305. PubMed ID: 20034330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients.
    Haas S
    Semin Thromb Hemost; 1999; 25 Suppl 3():101-5. PubMed ID: 10549724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic and practical aspects of thromboprophylaxis with unfractionated and low-molecular-weight heparins in hospitalized medical patients.
    Pineo GF; Hull RD
    Clin Appl Thromb Hemost; 2009 Oct; 15(5):489-500. PubMed ID: 19520676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis of thrombosis with low-molecular-weight heparin (LMWH).
    Holzheimer RG
    Eur J Med Res; 2004 Mar; 9(3):150-70. PubMed ID: 15096326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight heparins in the outpatient management of venous thromboembolism.
    Bick RL
    Semin Thromb Hemost; 1999; 25 Suppl 3():97-9. PubMed ID: 10549723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effectiveness and safety of low-molecular weight heparin versus unfractionated heparin anticoagulation after heart valve surgery.
    Bucci C; Geerts WH; Sinclair A; Fremes SE
    Am J Cardiol; 2011 Feb; 107(4):591-4. PubMed ID: 21184996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacoeconomics of deep vein thrombosis treatment.
    Shorr AF
    Am J Med; 2007 Oct; 120(10 Suppl 2):S35-41. PubMed ID: 17916458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin.
    Harenberg J; Huisman MV; Tolle AR; Breddin HK; Kirchmaier CM
    Semin Thromb Hemost; 2001 Oct; 27(5):513-8. PubMed ID: 11668421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis.
    Shorr AF; Jackson WL; Weiss BM; Moores LK
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):309-16. PubMed ID: 17473570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Sarasin FP; Bounameaux H
    Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 77.